Vanguard Group Inc Aclaris Therapeutics, Inc. Transaction History
Vanguard Group Inc
- $5.97 Trillion
- Q2 2025
A detailed history of Vanguard Group Inc transactions in Aclaris Therapeutics, Inc. stock. As of the latest transaction made, Vanguard Group Inc holds 6,662,063 shares of ACRS stock, worth $12.4 Million. This represents 0.0% of its overall portfolio holdings.
Number of Shares
6,662,063
Previous 4,970,254
34.04%
Holding current value
$12.4 Million
Previous $7.6 Million
24.41%
% of portfolio
0.0%
Previous 0.0%
Shares
18 transactions
Others Institutions Holding ACRS
# of Institutions
98Shares Held
87.6MCall Options Held
0Put Options Held
0-
Bml Capital Management, LLC Zionsville, IN14.3MShares$26.5 Million15.31% of portfolio
-
Adage Capital Partners Gp, L.L.C. Boston, MA9.63MShares$17.9 Million0.02% of portfolio
-
Vivo Capital, LLC Palo Alto, CA8.89MShares$16.5 Million2.67% of portfolio
-
Rock Springs Capital Management LP Baltimore, MD4.77MShares$8.87 Million0.46% of portfolio
-
Decheng Capital LLC Menlo Park, CA4.04MShares$7.52 Million1.45% of portfolio
About Aclaris Therapeutics, Inc.
- Ticker ACRS
- Exchange NASDAQ
- Sector Healthcare
- Industry Diagnostics & Research
- Shares Outstandng 66,671,800
- Market Cap $124M
- Description
- Aclaris Therapeutics, Inc. operates a clinical-stage biopharmaceutical company, develops novel drug candidates for immune-inflammatory diseases in the United States. It operates through two segments: Therapeutics and Contract Research. The Therapeutics segment is involved in identifying and developing innovative therapies to address significant ...